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Here, we use a vaccine consisting of DNA priming followed by MVA boosting in rhesus macaques to investigate the ability of GM-CSF DNA
to serve as an adjuvant for the elicitation of neutralizing Ab against an HIV-1 Env. The trial used Gag, Pol, and Env sequences from SHIV-89.6 in
the immunogens and a neutralization escape variant of SHIV-89.6, SHIV-89.6P, for challenge. Co-delivery of GM-CSF and vaccine DNAs
enhanced the temporal appearance of neutralizing Ab and broadened the specificity of the neutralizing activity to include SHIV-89.6P. Two long-
term SHIV-89.6 infections elicited neutralizing activity for SHIV-89.6 but not SHIV-89.6P. Studies on the avidity of the anti-Env antisera revealed
that the GM-CSF-adjuvanted vaccine had elicited higher avidity Ab than the non-adjuvanted vaccine or the infection. The GM-CSF-adjuvanted
group showed a trend towards better control of the challenge infection and had better control of re-emergent virus (P < 0.01) than the non-
adjuvanted group.
© 2006 Elsevier Inc. All rights reserved.Keywords: Immunodeficiency virus vaccine; DNA/MVA vaccine; GM-CSF DNA adjuvant; Neutralizing Ab; Avidity of Ab; Re-emergent virus protectionIntroduction
Recently, good progress has been made on the development
of HIV/AIDS vaccines that elicit high frequencies of anti-viral
T cells (Letvin, 2005; Robinson, 2002). In preclinical models,
these vaccines prevent disease by controlling infections. In
order to prevent infection, HIV/AIDS vaccines will need to
elicit neutralizing Ab capable of blocking infections before they
establish latency. Neutralizing antibodies capable of blocking
primary isolates of HIV-1 have proven difficult to generate due⁎ Corresponding author. 954 Gatewood Road NE, Atlanta, GA 30329, USA.
Fax: +1 404 727 7768.
E-mail address: hrobins@rmy.emory.edu (H.L. Robinson).
0042-6822/$ - see front matter © 2006 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2006.02.011to the selection of these proteins for neutralization resistance.
The envelope glycoproteins (Env) of HIV-1 are heavily
glycosylated and conceal conserved receptor and co-receptor
binding sites under loops of highly variable sequences (Burton,
1997; Kwong et al., 2002; Wyatt et al., 1998). In natural HIV
infections, the first neutralizing antibodies are directed against
variable loop sequences and typically recognize the infecting
virus, but not other isolates of HIV-1 (Etemad-Moghadam et al.,
1998; Richman et al., 2003; Wei et al., 2003). With time,
neutralizing antibodies with activity for other isolates of HIV-1
can appear (Carotenuto et al., 1998; Moog et al., 1997; Pilgrim
et al., 1997). Monoclonal antibodies representing this broader
activity target conserved neutralization domains such as the
CD4 binding site, the CD4-induced co-receptor binding site,
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al., 1998; Zolla-Pazner, 2004). One monoclonal has been found
that targets a glycosyl group and neutralizes by coating virus
particles (Calarese et al., 2003).
A unifying characteristic for all neutralizing antibodies is
their affinity. Broadly neutralizing monoclonal Ab have good
affinities (∼1 nM) that allow them to out-compete cellular
receptors for Env binding (Parren et al., 1998). Low affinity
monoclonal antibodies with similar target specificities fail to
block infections because sufficient titers of Ab cannot be
achieved to compete with receptor binding. The 2G12
monoclonal Ab against glycosyl groups has good affinity
(2.5 nM). Its ability to coat a virus particle presumably
contributes to its ability to neutralize and opens the possibility
that other high affinity Ab capable of coating the native forms of
virus particles could be neutralizing (Parren and Burton, 2001).
In simian models of immunodeficiency virus infections, the
appearance of neutralizing Ab capable of blocking heterologous
infections correlates with the avidity maturation of the Ab
response (Clements et al., 1995; Cole et al., 1997).
In this study, we investigate the ability of granulocyte-
macrophage-colony stimulating factor (GM-CSF) DNA to
serve as an adjuvant for enhancing anti-Env Ab responses
elicited by a vaccine that consists of DNA priming and MVA
boosting (DNA/MVA) (Amara et al., 2001). In mouse models,
the use of GM-CSF DNA as an adjuvant for DNA vaccines has
consistently enhanced antibody and CD4 T cell responses
(Barouch et al., 2002; Geissler et al., 1997; Kamath et al., 1999;
Lee et al., 1998; Pasquini et al., 1997; Sin et al., 1998; Wei et al.,
2003; Weiss et al., 1998; Xiang and Ertl, 1995). The
mechanisms for enhancing Ab responses are not understood.
However, it is known that the co-administration of GM-CSF
DNAwith a DNAvaccine recruits and stimulates the maturation
of antigen-presenting cells (Haddad et al., 2000; McKay et al.,
2004).
In primate models, GM-CSF DNA has had more modest
effects than in mouse studies. Studies in rhesus suggest the
elicitation of increased levels of malaria-specific Ab following
addition of GM-CSF DNA or GM-CSF protein to DNA
vaccines but limited changes in T cell responses (Kumar et al.,
2002). Immunizations combining GM-CSF, IL-4, and TNF-α
DNAs further increased Ab responses over responses obtained
with GM-CSF DNA alone (Rogers et al., 2002). In humans, in a
study in which Ab responses were not measured, the addition of
GM-CSF DNA to malaria DNAs appeared to reduce the
frequency of volunteers scoring for CD8 T cells but have no
effect on CD4 T cell responses (Wang et al., 2005).
Here, we study the effect of GM-CSF DNA on Ab responses
to the HIV Env using chimeras of simian and human
immunodeficiency viruses in which the Env is derived from
HIV-1. The studies include analysis for effects during
immunization as well as post-challenge. Our trial uses Gag,
Pol, and Env sequences from SHIV-89.6 for immunization and
SHIV-89.6P for challenge (Karlsson et al., 1997; Reimann et al.,
1996a, 1996b). SHIV-89.6P is a pathogenic neutralization
escape mutant, which emerged during serial passage of the non-
pathogenic SHIV-89.6 in macaques (Montefiori et al., 1998;Reimann et al., 1996a). The 89.6P Env differs from the 89.6
Env by 12 amino acids in the extracellular domains of gp120
and gp41 (Karlsson et al., 1997). These amino acid differences
result in the 89.6P Env being highly fusogenic and causing the
rapid decline of CD4 T cells in infected animals (Etemad-
Moghadam et al., 2001). Although the SHIV-89.6P Env can
exhibit dual tropism in in vitro studies, it preferentially uses the
CXCR-4 co-receptor present on naive CD4 T cells in infected
macaques (Cheng et al., 1993). Both SHIV-89.6 and SHIV-
89.6P are like incident infections in humans in eliciting type-
specific neutralizing Ab early after infection (Richman et al.,
2003; Wei et al., 2003). Their overall susceptibility to
neutralization by heterologous sera from infected patients is
similar to that for typical incident strains of clade B HIV-1 (Li et
al., 2005) (L. Lai, D. Montefiori, and H. Robinson, work in
progress).
Results
Vaccine trial and T cell responses
To test the adjuvant activity of GM-CSF for our Gag–Pol–
Env DNA/MVA vaccine, macaques were immunized at 0 and
8 weeks by single intradermal saline deliveries of 0.25 mg of a
SHIV-89.6 Gag–Pol–Env-expressing DNA (DNA/89.6) in the
presence or absence of 0.25 mg of a rhesus macaque GM-CSF-
expressing DNA (Fig. 1A). At 24 weeks, both groups were
boosted in the absence of GM-CSF with 2 × 108 pfu of a SHIV-
89.6 Gag–Pol–Env-expressing MVA (MVA/SHIV-89.6). The
virulent SHIV-89.6P challenge was administered intrarectally at
7 months after the MVA boost. Sera and peripheral blood
mononuclear cells were collected throughout the immunization
and post-challenge periods to monitor immune responses. The
temporal frequencies of ELISPOTS peaked after the MVA
boost and then again after the challenge, similar to previously
reported findings (Amara et al., 2001). The GM-CSF-
adjuvanted group showed a trend toward lower frequencies of
IFN-γ ELISPOTs than in the non-GM-CSF group (Fig. 1B).
This trend, however, was not significant.
In contrast to the T cell responses, the GM-CSF did affect the
anti-Env Ab responses (Fig. 2). DNA immunizations, with or
without GM-CSF, did not elicit detectable levels of SHIV-
specific antibodies (data not shown). However, the inclusion of
GM-CSF in the priming immunizations increased the titers of
anti-Env Ab raised by the MVA boost. Binding antibody for
Env was detected immediately post the MVA boost in all 6 of
the animals receiving GM-CSF adjuvanted DNA immuniza-
tions, but in only one of the six animals receiving non-
adjuvanted immunizations (Fig. 2).
Studies on neutralizing Ab and the post-challenge anamestic
Ab response
Neutralizing Ab was studied both during the immuniza-
tion phase of the trial and during the anamnestic Ab
response that occurred in the 1st 5 weeks post-challenge
(Fig. 3). During the immunizations, neutralizing antibodies
Fig. 1. Vaccine Trial and T cell responses. (A) Schematic showing the times of immunization and challenge. (B) IFN-γ ELISPOT responses at 1 week post the MVA
boost (peak vaccine response) and at 2 weeks post-challenge (peak post-challenge response). The numbers above the bars indicate the geometric means for each group.
Labels at the top indicate the group under test and numbers at the bottom, the monkey being tested. The # sign indicates the absence of a sample. SFU, spot forming unit.
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detected in the GM-CSF-adjuvanted group at the pre-
challenge bleed (Fig. 3A). Unexpectedly, this neutralizing
activity, while of low titers, was effective not only against
the homologous SHIV-89.6, but also the neutralization
escape variant, SHIV-89.6P. Neutralizing antibodies for
SHIV-89.6 and SHIV-89.6P were detected in each of the 5
tested animals from the GM-CSF-adjuvanted group but were
not detected in the six animals that did not receive the GM-
CSF adjuvant. Vaccine-elicited neutralizing antibodies also
have not been detected in 26 other animals receiving ourFig. 2. Vaccine-elicited anti-Env binding Ab. Data are for the peak response at 3
weeks after the MVA boost (27 weeks in trial). Each bar indicates an individual
animal. The numbers above the bars indicate the geometric means for each
group. Labels at the top indicate the group under test and numbers at the bottom,
the monkey being tested.non-adjuvanted DNA/MVA SHIV-89.6 vaccine (Amara et al.,
2001; Buge et al., 2003).
Post-challenge, comparison of the anamnestic responses in
the plus and minus GM-CSF groups revealed similar temporal
patterns for binding Ab, but different temporal patterns for
neutralizing Ab (Fig. 3B). In both groups, the anamnestic
response for binding Ab peaked by 5 weeks post-challenge. In
contrast, peak titers of neutralizing Ab for SHIV-89.6P occurred
at 5 weeks post-challenge in the plus GM-CSF group, but at 12
weeks post-challenge in the minus GM-CSF group. Thus, the
GM-CSF appeared to have primed an Ab response capable of
neutralizing SHIV-89.6P.
Next, sera from two macaques that had been infected for 3.8
years with SHIV-89.6 were tested for neutralizing Ab.
Consistent with prior trials, these sera exhibited good
neutralizing activity for SHIV-89.6 but failed to neutralize
SHIV-89.6P, suggesting that the GM-CSF-adjuvanted vaccine
had primed neutralizing Ab with greater breadth than elicited by
SHIV-89.6 infection.
Further studies on neutralizing Ab
A screen for neutralizing activity against a panel of primary
isolates revealed that the DNA/MVA immunizations had primed
neutralizing activity that extended to one isolate that is highly
sensitive to neutralization: HIV-1-SF-162 and a 2nd isolate that
has intermediate sensitivity, HIV-1-BX-08. These responses
were low prior to challenge (<100) but underwent strong
anamnestic responses post-challenge.
Fig. 3. Priming of neutralizing antibody for SHIV-89.6 and SHIV-89.6P in the GM-CSF-plus, but not the minus GM-CSF vaccine groups. (A) Time course for the
appearance of neutralizing Ab for SHIV-89.6 and SHIV-89.6P in the two vaccine groups. Each bar indicates an individual animal. Filled bars are neutralizing activity
for SHIV-89.6 and hatched bars for SHIV-89.6P. The # sign indicates the absence of serum. The numbers above the bars indicate the geometric means for each group.
Labels at the top indicate the group under test; labels on the right, the time in the trial, and numbers at the bottom, the monkey being tested. (B) Temporal appearance
during the post-challenge anamestic response of binding Ab for SHIV-89.6 and neutralizing Ab for SHIV-89.6P. The vertical dotted lines indicate the time of challenge.
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groups were pooled, blinded, the IgG purified, and neutraliza-
tion tests confirmed. The purified IgG from the post-challenge
response in the two vaccine groups neutralized SHIV-89.6P, SF-
162, and BX-08 (Fig. 4). Consistent with the temporal post-
challenge appearance of neutralizing Ab for SHIV-89.6P (Fig.
3B), the plus GM-CSF group achieved 50% neutralization of
SHIV-89.6P with lower amounts of IgG than the minus GM-
CSF group. Also consistent with the neutralization assays using
sera, the purified IgG from the SHIV-89.6 infected animal
neutralized SF-162 but not BX-08 or SHIV-89.6P.
Assays for avidity maturation of the Ab response
Assays were next undertaken to test whether GM-CSF had
served as an adjuvant for the avidity maturation of the anti-Env
Ab response and whether the vaccines were raising higher
avidity Ab than the infection (Fig. 5). The avidity assays used
ELISAs to measure the ability of the chaotropic agent NaSCN
to displace IgG from a secreted oligomeric form of the 89.6 Env(89.6 gp140). Avidity assays were conducted on IgG that had
been titrated in a standard ELISA to identify a dilution that
scored near the high end of the linear portion of the binding
curve. The end point for the assay was the molarity of NaSCN
required to achieve a 50% reduction in the optical density
reading for bound anti-Env Ab (for example of an assay, see
Fig. 5A).
The avidity assays revealed anti-Env Ab undergoing avidity
maturation over time (Fig. 5B). The anti-Env Ab elicited by the
GM-CSF-adjuvanted vaccine achieved the highest avidity and
the Ab elicited by the non-adjuvanted vaccine, the 2nd highest
avidity. The SHIV-89.6 infection elicited the lowest avidity Ab
(Fig. 5B). At early points in the vaccine trial, or post-infection,
50% dissociation of the anti-Env Ab was achieved by <1 M
concentrations of NaSCN. However, by the time of challenge
and at 5 weeks post-challenge, anti-Env Ab in both the plus and
minus GM-CSF vaccine groups required 2–2.5 M NaSCN for
50% displacement (Fig. 5B). In contrast, at 3.8 years post-
infection, the SHIV-89.6-elicited Ab required only 1.7 M
NaSCN for 50% displacement.
Fig. 5. Avidity of IgG used in neutralization assays determined using NaSCN displacement. (A) Representative avidity assay for plate-bound 89.6 gp140. Low and high
designate low and high avidity controls. GM, GM-CSF; wk, week. (B) Summary of data obtained from the avidity assays. The bars represent the mean ± standard
deviation for the molarity of NaSCN required for 50% displacement of anti-Env binding Ab for 89.6 gp140. The # sign indicates that purified IgGwas not available. The
standard deviations represent 2 to 5 replicates per sample. Samples without an error bar represent assays for which sufficient IgG was present for only a single assay.
Fig. 4. Neutralizing activity in purified IgG. The viruses under test are indicated above columns and the source of the purified IgG at the right of the panels. Purified
IgG for the plus and minus GM-CSF groups are from 5 weeks post-challenge. Purified IgG for the SHIV-89.6 group is from 3.8 years post-infection. Dotted vertical
lines indicate the 50% titers of neutralizing activity. Repeat values on samples for which sufficient sera were available indicated that the concentrations of IgG required
for 50% neutralization could vary by as much as 10-fold.
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Fig. 6. Post-challenge viremia. (A) Titers of viral RNA and (B) frequencies of infected CD4 cells in blood for the various groups at 2 weeks post-challenge. The
horizontal dashes indicate the geometric means. Cont, Controls. (C) Temporal titers of post-challenge viremia for the 1st one and one half years post-challenge. †, death
of an animal.
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The GM-CSF-adjuvanted vaccine controlled the mucosally
delivered challenge infection better than the non-adjuvanted
vaccine (Fig. 6). At 2 weeks post-challenge, there was a trend
for better control. The geometric mean for the peak titer of
plasma viral RNA in the GM-CSF-adjuvanted group (1.5 × 107)
was about 4 times lower than the peak titer in the non-
adjuvanted group (5.5 × 107) and 20 times lower than the
3.3 × 108 peak in the unvaccinated control animals (Fig. 6A).
The frequencies of infected CD4 cells had a geometric mean of
0.1% in the plus GM-CSF group, 1.0% in the minus GM-CSF
group and 4% in the control group (Fig. 6B). Between 3 and 12
weeks post-challenge, the rate and magnitude of virus control
were similar in both groups (Fig. 6C). However, between 28 and
52 weeks, the GM-CSF group showed significantly tighter
control of re-emergent virus than the non-GM-CSF group
(P < 0.01). Of the 6 animals in the GM-CSF group, 5 did not
exhibit low level peaks of re-emergent virus while one exhibited
one very low peak. In contrast, in the non-adjuvanted group, all
6 animals exhibited low peaks of re-emergent virus with the
median number of peaks being 2. After 52 weeks, the non-GM-
CSF group continued to show some peaks of re-emergent viruswhereas the GM-CSF group continued to maintain control
below our level of detection.
All of the vaccinated animals protected their CD4 Tcells from
the rapid loss associated with SHIV-89.6P challenge and did not
exhibit disease whereas the unvaccinated controls underwent the
expected rapid loss of CD4 cells and 5 of 6 succumbed to AIDS
within a year of infection (Fig. 6C). At 2 1/2 years post-
challenge, the GM-CSF-adjuvanted group was entered into a
CD8 depletion study (Amara et al., 2005). The depletion resulted
in the rapid re-emergence of virus, demonstrating a critical role
for CD8 T cells in the continuing control of the infection. The
non-GM-CSF group was euthanized at 4 years after challenge, a
time at which the animals were disease-free but still suffering
low frequencies of transient low levels of re-emergent virus.
Discussion
A central problem faced by HIV vaccines is the raising of
neutralizing Ab for primary isolates. Here, we show that GM-
CSF can serve as an adjuvant for the broadening of the
neutralizing Ab response for SHIV-89.6 to its SHIV-89.6P
neutralization escape variant. Consistent with prior findings,
natural infection with SHIV-89.6 elicited neutralizing Ab for
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other primary isolates revealed both the GM-CSF and non-
GM-CSF-adjuvanted vaccines eliciting neutralizing activity
for two primary isolates: the highly sensitive HIV-1-SF-162
and the moderately sensitive HIV-1-BX-08. The SHIV-89.6
sera had a narrower neutralization potential, neutralizing only
HIV-1-SF-162.
The GM-CSF-adjuvanted and non-adjuvanted vaccine
groups had similar time courses for the appearance of post-
challenge binding Ab, but different time courses for the
appearance of neutralizing Ab for SHIV-89.6P, which appeared
first in the GM-CSF-adjuvanted group. Thus, during the 8 weeks
immediately post-challenge, the GM-CSF group had broader
neutralizing activity per ELISA unit of anti-Env Ab than the
non-GM-CSF group. Studies on the avidity of the Ab responses
were consistent with the avidity of Ab for the 89.6 Env,
correlating with the breadth of neutralizing activity and with the
vaccine-elicited Ab undergoing better avidity maturation than
the infection-elicited Ab. GM-CSF appeared to have accentu-
ated this phenomenon, with the plus GM-CSF group having
higher avidity Ab than the minus GM-CSF group. Avidity
maturation of the Ab response takes place in lymph node
germinal center reactions where Ab undergoes hypermutation
and selection for affinity. Entry into a germinal center reaction
requires conjugation of cognate CD4 T and B cells. Immuno-
deficiency virus infections preferentially kill anti-viral CD4 T
cells (Douek et al., 2002; Horton et al., 2002) and may therefore
be poor at providing CD4 help for the anti-Env Ab response.
Thus, a vaccine may be able to prime both higher avidity and
broader neutralizing Ab than its cognate infection by providing
better CD4 T cell help for the anti-Env B cell response.
The ability of GM-CSF to augment the avidity maturation of
the Ab response has been observed in this trial as well as an
ongoing repeat trial (work in progress). GM-CSF recruits and
stimulates the maturation of antigen-presenting cells (Haddad et
al., 2000). In macaques and humans, dendritic cells differentiate
into at least two major lineages: plasmacytoid and myeloid
(Ardavin et al., 2001; Coates et al., 2003; Shortman and Liu,
2002). These lineages differ in their ability to produce TNF-α
(plasmacytoid) and IL-12 (myeloid). In mice, GM-CSF favors
the elicitation of dendritic cells that produce IL-4 and IL-10
(Daro et al., 2000). The types of dendritic cells expanded in
macaques have not been defined. For example, avidity
maturation of the Ab response could be favored by GM-CSF
preferentially eliciting dendritic cells that favor CD4 T cell
trafficking to germinal centers. Such T cells are designated TFH
and display the CXCR5 chemokine receptor (Breitfeld et al.,
2000; Mackay, 2000; Schaerli et al., 2000). GM-CSF might also
affect Ab responses by influencing the ability of dendritic cells
to traffic to germinal centers for local antigen presentation and
stimulation of B cell responses.
In addition to fostering the neutralizing activity of the anti-
Env Ab responses, the GM-CSF adjuvant also improved the
long-term control of the post-challenge infection as measured by
the frequency of low level peaks of re-emergent virus (P < 0.01).
In our ongoing repeat experiment, GM-CSF has again fostered
better control of the SHIV-89.6P challenge, reducing peak aswell as early set point viremia by 10-fold. In the repeat trial,
additional MVA boosts supported the maturation of neutralizing
Ab for SHIV-89.6P in the minus GM-CSF group and both
groups underwent similar post-challenge expansions of neutral-
izing Ab for SHIV-89.6P. Again, the GM-CSF adjuvant did not
increase ELISPOT responses in PBMC. Thus, we have
reproducibly found higher avidity Ab and better protection for
the GM-CSF-adjuvanted vaccine, but do not have SHIV-89.6P
neutralizing Ab as a clear correlate for this improved protection.
Materials and methods
Immunogens
The construction and production of DNA and MVA
immunogens have been previously described (Amara et al.,
2001). The SHIV-89.6 DNA (DNA/89.6) expressed Gag, Pol,
Env, Tat, Rev, Vif, Vpr, and Vpu using the pGA expression
vector. This expression vector uses sequences from the CMV
immediate early gene as a promoter and sequences from the
bovine growth hormone polyadenylation sequence for termina-
tion. The MVA (MVA/89.6) expressed SHIV-89.6 Gag, Pol, and
Env using a synthetic early/late promoter and insertion sites III
and II, respectively (Amara et al., 2001). The 89.6 Env protein in
the MVAwas truncated for the COOH-terminal 115 amino acids
of gp41. A rhesus macaque GM-CSF DNA provided by the
Resource for Nonhuman Primate Reagents (Emory University)
was expressed by subcloning the gene with its signal sequence in
the pGA expression vector (Hutchinson et al., 2001).
Immunizations and challenge
Young adult rhesus macaques from the Yerkes breeding
colony were cared for under guidelines established by the
Animal Welfare Act and the NIH “Guide for the Care and Use
of Laboratory Animals” using protocols approved by the Emory
University Institutional Animal Care and Use Committee. All
vaccinated animals received a single inoculation of 0.25 mg of
DNA/89.6 intradermally at 0 and 8 weeks and 2 × 108 pfu of
MVA/SHIV-89.6 delivered both intradermally and intramuscu-
larly at 24 weeks. The GM-CSF-adjuvanted group received
0.25 mg of DNA expressing macaque GM-CSF mixed with
0.25 mg of DNA/89.6 as single intradermal inoculations at
weeks 0 and 8. Control animals received vector DNA without
vaccine inserts at 0 and 8 weeks and MVA without an insert at
24 weeks. At 7 months after the MVA, booster animals received
an intrarectal challenge with SHIV-89.6P using a pediatric
feeding tube to introduce 20 intrarectal infectious units
(1.2 × 1010 copies of SHIV-89.6P viral RNA) 15 to 20 cm
into the rectum. SHIV copy number was determined using a
quantitative real-time PCR as previously described (Amara et
al., 2001; Hofmann-Lehmann et al., 2000). All specimens were
extracted and amplified in duplicate, with the mean result
reported. Animal numbers are as follows: 13, RKw-4*; 14,
RWz-5*; 15, RGo-5; 16, RLp-4; 17, RWd-6; 18, RAt-5; 25,
RMb-5*; 26, RGy-5*; 27, RUs-4; 28, RPm-5; 29, RPs-4; 30,
RKj-5; 49, REz-5*; 50, RGw-4; 51, RPa-5; 52, RQv-4*; 53,
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with asterisks. Symbols used for individual macaques can be
found in Fig. 2B. Some data for animals in the non-adjuvanted
group are reported in Amara et al. (2001).
Binding Ab
ELISAs for total anti-Env antibody were carried out on EIA/
RIA high binding polystyrene 96-well plates (Costar, Corning
Life Sciences, Acton, MA). Standard curves were generated
using goat anti-monkey IgG (Accurate Chemical and Scientific
Corp, Westbury, NY) to capture rhesus IgG (Sigma, St. Louis,
MO). Wells were coated overnight at 4 °C with 200 ng of the
capture Ab in 0.05 M carbonate buffer, pH 9.6 (carbonate
buffer), blocked for 1 h at room temperature with 4% whey, 5%
non-fat dry milk in PBS (blocking buffer), and then used to
capture a serial 2-fold dilution series of rhesus IgG starting at
20 ng per well in PBS plus 4% whey. For test samples, wells on
the same plates were coated overnight at 4°C with a secreted
form of the ectodomain of the 89.6 Env (89.6 gp140) at 20 ng
per well or a secreted receptor binding subunit of HIV-1-Bal
(Bal gp120) (Quality Biologics, Gaithersberg, MD) at 200 ng
per well in carbonate buffer and then blocked for 1 h with
blocking buffer. Test sera were incubated in duplicate wells at 3-
fold dilutions in PBS plus 4% whey for 1 h at room temperature.
Plates were washed 6 times with PBS plus 0.05% Tween 20,
and bound Ab was detected using peroxidase-conjugated goat
anti-macaque IgG (Accurate Chemical and Scientific Corp,
Westbury, NY) and TMB substrate (KPL, Gaithersburg, MD).
Reactions were stopped with 100 μl of 2 N H2SO4. Standard
curves were fitted, and sample concentrations were interpolated
as μg of Ab per ml of serum using SOFTmax 2.3 software
(Molecular Devices, Sunnyvale, CA).
Neutralization assays
The titers of neutralizing antibody for SHIV-89.6 and SHIV-
89.6P were determined using MT-2 cell killing and neutral red
staining (Montefiori et al., 1988). Neutralization titers are the
reciprocal of the serum dilution required to protect 50% of cells
from the killing effects of the indicated viruses grown in human
PBMC. This cut-off corresponds to an approximate 90%
reduction in virus yield (Bures et al., 2000). Neutralizing antibody
assays were performed blinded. The titers of neutralizing Ab for
primary isolates were determined using a luciferase reporter gene
assay in 5.25.EGFP.Luc.M7 cells (Montefiori, 2004). IgG
samples were screened in endpoint assays for the concentration
of serum required to achieve a 50% reduction in RLU.
Avidity assays
Avidity assays were conducted using purified IgG which had
been titrated for binding Ab against 89.6 gp140 to identify
concentrations giving ODs that were at the high end of the linear
range for binding curves (typically an OD of 0.6 to 0.7 on a
binding curve that was linear from an OD of 0.2 to 0.8). These
concentrations of IgG were then tested on duplicate wells fordisplacement from Env during a 15-min incubation at room
temperature by increasing molarities of NaSCN prepared in
PBS immediately prior to use. Following the NaSCN treatment,
plates were washed 6 times with PBS plus 0.05% Tween and
scored for bound Ab as done in binding assays. The molarity of
NaSCN required for 50% displacement of bound sera was
estimated using optical densities, with the optical density of the
untreated sample being considered 100%. Each plate contained
a standard curve for macaque IgG to verify that the OD for
untreated samples was at the high end of the linear range of the
assay. Each plate also contained low and high avidity standards.
The low avidity standard consisted of pooled sera from 12
weeks post-challenge from a group of macaques that had
received a Gag–Pol without Env DNA/MVAvaccine (Amara et
al., 2002a). The high avidity standard was purified IgG from a
group of animals that had received three MVA/SHIV-89.6
immunizations (Amara et al., 2002b). The avidity assay was
highly reproducible with standard deviations for independent
determinations of <15%.
ELISPOT assays
Assays for IFN-γ ELISPOTs used pools of overlapping
peptides (22 mers overlapping by 10 for Gag and 15 mers
overlapping by 11 for Env) and were conducted as previously
described (Amara et al., 2001, 2002b).
Statistical analyses
Antibody levels, number of infected cells, viral load, and CD4
cell counts were compared for the GM-CSF-adjuvanted group
and non-adjuvanted groups at selected time points during the
study. Because the data distributions were typically skewed, we
used the non-parametric Wilcoxon test for independent samples.
When multiple tests were computed for the same measure for
different time points, the Bonferroni method was used to adjust
for the multiple comparisons. A two-sided P < 0.05 was
considered statistically significant. Analyses for differences in
the frequency of re-emergent virus noted the number of occasions
during the 6 samples obtained from weeks 28 to 70 in the trial on
which each animal had detectable levels of virus. The resulting
scores for the non-GM-CSF-adjuvanted group were 1, 1, 1, 3, 4,
and 6 (median = 2), while the scores for the GM-CSF-adjuvanted
group were 0, 0, 0, 0, 0, and 1 (median = 0). These scores were
analyzed for significance using the Wilcoxon test.
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